Do we need new treatments for type 2 diabetes?;¿Necesitamos nuevos tratamientos para la diabetes tipo 2?

Endocrinologia y Nutricion

Volumn 61, Issue 6, 2014, Pages 323-328

  Gomez Peralta, Fernando ^a   Abreu Padín, Cristina ^a  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

Author keywords

Antidiabetic drugs; Diabetes; Future treatment; Hypoglycemia; Weight

Indexed keywords

ANTIDIABETIC AGENT; NEW DRUG; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIPID;

HUMAN; HYPOGLYCEMIA; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; SHORT SURVEY; WEIGHT GAIN; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLASSIFICATION; COMORBIDITY; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; EXPERIMENTAL THERAPY; HEALTH SERVICE; INFLAMMATION; LIFE EXPECTANCY; METABOLIC SYNDROME X; MOTIVATION; OVERWEIGHT; OXIDATIVE STRESS; PERSONALIZED MEDICINE; RISK FACTOR; THROMBOPHILIA;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GOALS; HEALTH SERVICES NEEDS AND DEMAND; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; INFLAMMATION; INSULIN; LIFE EXPECTANCY; LIPIDS; METABOLIC SYNDROME X; OVERWEIGHT; OXIDATIVE STRESS; RISK FACTORS; THERAPIES, INVESTIGATIONAL; THROMBOPHILIA;

EID: 84902538070     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2013.10.013     Document Type: Short Survey

References (37)

1. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013, 36(Suppl 1):S67-S74. American Diabetes Association.
2. Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
3. Giugliano D., Standl E., Vilsbøll T., Betteridge J., Bonadonna R., Campbell I.W., et al. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. Acta Diabetol 2009, 46:173-181.
4. Giugliano D., Maiorino M.I., Bellastella G., Chiodini P., Esposito K. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review. Diabetes Res Clin Pract 2011, 92:1-10.
5. Pontiroli A.E., Miele L., Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: Systematic review and meta-analysis. Diabetes Obes Metab 2012, 14:433-446.
6. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007, 298:194-206.
7. Deacon C.F., Mannucci E., Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and metaanalysis. Diabetes Obes Metab 2012, 14:762-767.
8. Skyler J.S., Bergenstal R., Bonow R.O. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009, 32:187-192. American Diabetes Association; American College of Cardiology Foundation; American Heart Association.
9. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Presiss D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
10. Kelly T.N., Bazzano L.A., Fonseca V.A., Thethi T.K., Reynolds K., He J. Systematic review: Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394-403.
11. Ali M.K., Bullard K.M., Saaddine J.B., Cowie C.C., Imperatore G., Gregg E.W. Achievement of goals in U. S. diabetes care, 1999-2010. N Engl J Med 2013, 368:1613-1624.
12. Vinagre I., Mata-Cases M., Hermosilla E., Morros R., Fina F., Rosell M., et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care 2012, 35:774-779.
13. Rydén L., Standl E., Bartnik M., van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28:88-136. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD).
14. Fonseca V., McDuffie R., Calles J., Cohen R.M., Feeney P., Feinglos M., et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care 2013, 36:2162-2168. ACCORD Study Group.
15. Narayan K.M., Boyle J.P., Thompson T.J., Sorensen S.W., Williamson D.F. Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290:1884-1890.
16. Gregg E.W., Cheng Y.J., Saydah S., Cowie C., Garfield S., Geiss L., et al. Trends in death rates among U. S. adults with and without diabetes between 1997 and 2006: Findings from the National Health Interview Survey. Diabetes Care 2012, 35:1252-1257.
17. Morgan C.L., Jenkins-Jones S., Evans M., Barnett A.H., Poole C.D., Currie C.J. Weight change in people with type 2 diabetes: Secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab 2012, 14:424-432.
18. Davis S., Alonso M.D. Hypoglycaemia as a barrier to glycemic control. J Diabetes Complications 2004, 18:60-68.
19. Hsu P.F., Sung S.H., Cheng H.M., Yeh J.S., Liu W.L., Chan W.L., et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: A nationwide population-based study. Diabetes Care 2013, 36:894-900.
20. Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011, 365:2002-2012. 24.
21. Phung O.J., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
22. Goodarzi M.O., Bryer-Ash M. Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 2005, 7:654-665.
23. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116:1802-1812.
24. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 53(Suppl 3):S16-S21.
25. Wright A., Burden A.C., Paisey R.B., Cull C.A., Holman R.R. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25:330-336. U.K. Prospective Diabetes Study Group.
26. Holman R.R. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998, 40 Suppl:S21-S25.
27. Poitout V., Robertson R.P. Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143:339-342.
28. Decker M., Hofflich H., Elias A.N. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 2008, 10:617-625.
29. Del Prato S., Bianchi C., Marchetti P. Beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev 2007, 23:518-527.
30. Bertoni A.G., Burke G.L., Owusu J.A., Carnethon M.R., Vaidya D., Barr R.G., et al. Inflammation and the incidence of type 2 diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010, 33:804-810.
31. Phillips C.M., Perry I.J. Does inflammation determine metabolic health status in obese and nonobese adults?. J Clin Endocrinol Metab 2013, 98:E1610-E1619.
32. Stern M.P. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?. Ann Intern Med 1996, 124(1 Pt 2):110-116.
33. Cavelti-Weder C., Babians-Brunner A., Keller C., Stahel M.A., Kurz-Levin M., Zayed H., et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012, 35:1654-1662.
34. Biondi-Zoccai G.G., Abbate A., Liuzzo G., Biasucci L.M. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003, 41:1071-1077.
35. Stratton I.M., Cull C.A., Adler A.I., Matthews D.R., Neil H.A., Holman R.R. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75). Diabetologia 2006, 49:1761-1769.
36. Turnbull F.M., Abraira C., Anderson R.J., Byington R.P., Chalmers J.P., Duckworth W.C., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298. Control Group.
37. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.